Wedbush Comments on Ardelyx's FY2026 Earnings (NASDAQ:ARDX)

Key Points

• Wedbush has revised its FY2026 earnings estimate for Ardelyx down to $0.06 per share from $0.07, maintaining an "Outperform" rating with a target price of $14.00.
• Ardelyx reported a quarterly loss of ($0.08) earnings per share, which exceeded analysts' expectations of ($0.13), alongside a revenue increase of 23.0% year-over-year to $97.66 million.
• Institutional investors own 58.92% of Ardelyx's stock, with significant increases in holdings from firms like Vanguard and Two Sigma Advisers in recent quarters.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at Wedbush decreased their FY2026 earnings estimates for shares of Ardelyx in a research note issued on Tuesday, August 5th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.07. Wedbush has a "Outperform" rating and a $14.00 price objective on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's FY2028 earnings at $0.69 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $97.66 million for the quarter, compared to the consensus estimate of $82.69 million. Ardelyx had a negative return on equity of 35.44% and a negative net margin of 14.60%. The firm's revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.07) EPS.

A number of other equities analysts have also issued reports on the stock. Raymond James Financial reissued an "outperform" rating and set a $12.00 price target (up from $11.00) on shares of Ardelyx in a research report on Tuesday. HC Wainwright initiated coverage on shares of Ardelyx in a report on Wednesday, June 18th. They set a "buy" rating and a $10.00 target price for the company. Citigroup lowered their price target on shares of Ardelyx from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Wall Street Zen downgraded Ardelyx from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, UBS Group set a $12.00 price objective on Ardelyx in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $11.40.

Ardelyx Trading Up 16.9%

Ardelyx stock opened at $5.13 on Wednesday. The stock has a 50-day moving average price of $4.08 and a 200 day moving average price of $4.63. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -22.30 and a beta of 0.68. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18. The company has a quick ratio of 3.81, a current ratio of 4.12 and a debt-to-equity ratio of 1.04.

Insider Buying and Selling

In other news, insider Laura A. Williams sold 6,421 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total transaction of $26,197.68. Following the completion of the transaction, the insider directly owned 402,583 shares of the company's stock, valued at $1,642,538.64. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David M. Mott purchased 200,000 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was bought at an average cost of $3.63 per share, for a total transaction of $726,000.00. Following the purchase, the director directly owned 2,896,871 shares in the company, valued at $10,515,641.73. This trade represents a 7.42% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 500,000 shares of company stock valued at $1,793,000 and sold 83,477 shares valued at $340,586. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Ardelyx by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company's stock worth $72,819,000 after buying an additional 767,111 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Ardelyx by 206.7% in the fourth quarter. Two Sigma Advisers LP now owns 593,700 shares of the biopharmaceutical company's stock valued at $3,010,000 after acquiring an additional 400,100 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Ardelyx by 203.1% in the first quarter. SG Americas Securities LLC now owns 166,343 shares of the biopharmaceutical company's stock worth $817,000 after acquiring an additional 111,457 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Ardelyx by 32.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 578,256 shares of the biopharmaceutical company's stock worth $2,932,000 after purchasing an additional 142,294 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Ardelyx by 13.3% in the 4th quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company's stock valued at $123,587,000 after purchasing an additional 2,858,061 shares during the last quarter. Institutional investors and hedge funds own 58.92% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.